/
DXCM
$68.86+$1.51 (+2.24%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$26.0B
386M shares
52-week range
$54.11 – $89.98
41% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.28%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-39.04
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.03B | $1.48B | $1.93B | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B |
| Cost of revenue | $367.7M | $544.5M | $646.6M | $768.0M | $1.03B | $1.33B | $1.59B | $1.86B |
| Gross profit | $663.9M | $931.5M | $1.28B | $1.68B | $1.88B | $2.29B | $2.44B | $2.80B |
| Gross margin | 64.4% | 63.1% | 66.4% | 68.6% | 64.7% | 63.2% | 60.5% | 60.0% |
| R&D | $417.4M | $273.5M | $359.9M | $604.2M | $484.2M | $505.8M | $552.4M | $594.9M |
| Operating income | −$186.3M | $142.3M | $299.5M | $265.8M | $391.2M | $597.7M | $600.0M | $911.8M |
| EBITDA | −$74.7M | $213.2M | $376.8M | $377.5M | $565.3M | $916.7M | $945.7M | $1.36B |
| Net income | −$127.1M | $101.1M | $493.6M | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M |
| Net margin | -12.3% | 6.8% | 25.6% | 8.9% | 11.7% | 14.9% | 14.3% | 17.9% |
| EPS (diluted) | -0.36 | 0.27 | 1.27 | 0.51 | 0.80 | 1.30 | 1.42 | 2.09 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5.2B | $2.59 | $2.47–$2.67 | 14 |
| 2027 | $5.8B | $3.09 | $2.87–$3.31 | 15 |
| 2028 | $6.5B | $3.69 | $2.95–$3.96 | 5 |
| 2029 | $7.3B | $4.31 | $4.24–$4.38 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$47.33
Price
$68.86
Implied downside
-31%
Peer comparison
DexCom, Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
www.dexcom.com- Employees
- 11,100
- IPO / List date
- Apr 14, 2005
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds DXCM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,582,996 | $99.4M |
| Bridgewater Associatesas of 2026-03-31 | 139,687 | $8.8M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2022-06-13 | 4-for-1 |
Recent trades on TradeandTell
No one on the platform has traded DXCM yet.
